Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ovemotide SCHEMBL29413273 | 1.00 | CALCRL (0.56) | CALCRLSLC6A2RAMP1RENNTSR2 | |
| SCHEMBL29449529 | 0.96 | CALCRL (0.56) | CALCRLSLC6A2RAMP1RENOPRD1 | |
| SCHEMBL30974436 | 0.92 | CALCRL (0.52) | CALCRLSLC6A2NTSR2NTSR1OPRD1 | |
| SCHEMBL29530922 | 0.88 | SLC6A2 (0.64) | CALCRLSLC6A2NTSR2NTSR1OPRD1 | |
| SCHEMBL31575684 | 0.86 | KDM1A (0.56) | SLC6A2NTSR2NTSR1KEAP1 | |
| SCHEMBL29531376 | 0.85 | SLC6A2 (0.72) | CALCRLSLC6A2OPRD1 | |
| SCHEMBL29530548 | 0.85 | SLC6A2 (0.72) | CALCRLSLC6A2OPRD1 | |
| SCHEMBL30792437 | 0.84 | NMUR2 (0.56) | — | |
| SCHEMBL31410876 | 0.83 | CALCRL (0.49) | CALCRLSLC6A2RAMP1NTSR2NTSR1 | |
| SCHEMBL29531383 | 0.81 | SLC6A2 (0.71) | CALCRLSLC6A2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646428-A1 | METHODS AND COMPOSITIONS FOR GENE TRANSDUCTION AND TO CONTROL THE ACTIVITY OF SYNTHETIC AND IMMUNE RECEPTORS | Angeles Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024148337-A1 | METHODS AND COMPOSITIONS FOR GENE TRANSDUCTION AND TO CONTROL THE ACTIVITY OF SYNTHETIC AND IMMUNE RECEPTORS | ANGELES THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230391846-A1 | MODIFIED SOLUBLE T CELL RECEPTOR | WuXi Biologics Ireland Limited (IE) | 2023-12-07 | — | — | US | disclosed |
| EP-4237437-A1 | MODIFIED SOLUBLE T CELL RECEPTOR | Wuxi Biologics Ireland Limited (IE) | 2023-09-06 | — | — | EP | disclosed |
| CN-116457374-A | Modified soluble T cell receptor | 上海药明生物技术有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022089569-A1 | MODIFIED SOLUBLE T CELL RECEPTOR | WUXI BIOLOGICS (SHANGHAI) CO., LTD. (CN) | 2022-05-05 | — | — | WO | disclosed |